Delivers on the Promise of Proteomics
Our unique assays enable the real-time monitoring of protein biomarkers and drug targets. Many oncology therapeutics function by altering the post-translational modifications occurring to the actual drug target or downstream proteins within the targeted pathway. Understanding what is happening at the protein level, including their activation status and post-translational modifications such as phosphorylation, acetylation, and glycosylation, is critical for understanding a drug's MOA, diagnosing and monitoring disease progression, establishing individual prognosis, confirming genomic predictions, and tracking treatment responses.
MDI works side-by-side with pharmaceutical companies, helping them do faster and more confident drug discovery and clinical development.
For more information regarding MDI's capabilities please Contact Us